Llovet, Josep M. http://orcid.org/0000-0003-0547-2667
Pinyol, Roser http://orcid.org/0000-0002-0288-6314
Yarchoan, Mark http://orcid.org/0000-0003-4401-0748
Singal, Amit G. http://orcid.org/0000-0002-1172-3971
Marron, Thomas U. http://orcid.org/0000-0001-5903-8191
Schwartz, Myron http://orcid.org/0000-0002-9113-886X
Pikarsky, Eli http://orcid.org/0000-0003-4186-7105
Kudo, Masatoshi http://orcid.org/0000-0002-4102-3474
Finn, Richard S. http://orcid.org/0000-0003-2494-2126
Article History
Accepted: 2 February 2024
First Online: 29 February 2024
Competing interests
: J.M.L. receives research support from Bayer HealthCare Pharmaceuticals, Eisai Inc. and Sagimet; has received consulting fees from AstraZeneca, Bayer HealthCare Pharmaceuticals, Bristol–Myers Squibb, Eisai Inc., Exelixis, Genentech, Glycotest, Merck, Moderna and Roche. M.Y. has received institutional research support from Bristol–Myers Squibb, Genentech and Incyte; honoraria from Astrazeneca, Eisai, Exelixis, Genentech, Hepion and Replimune; and is a co-founder of and holds equity in Adventris Pharmaceuticals. A.G.S. has served as a consultant or on advisory boards for AstraZeneca, Bayer, Boston Scientific, Eisai, Exact Sciences, Exelixis, Freenome, FujiFilm Medical Sciences, GRAIL, Genentech, Glycotest, Roche and Universal Dx. T.U.M. has served on advisory and/or data safety monitoring boards for AbbVie, Arcus, Astellas, AstraZeneca, Atara, Boehringer Ingelheim, Bristol–Meyers Squibb, Celldex, Chimeric, DBV Technologies, DrenBio, G1 Therapeutics, Genentech, Glenmark, Merck, NGMbio, Regeneron, Rockefeller University, Simcere and Surface; and received research grants from Boehringer Ingelheim, Bristol–Myers Squibb, Merck and Regeneron. M.K. has received research support from Bayer Pharmaceutical, Chugai, Eisai, Ono Pharmaceutical and Takeda; consultancy or lecture fees from AbbVie, AstraZeneca, Bayer, Chugai, EA Pharma, Eisai, Eli Lilly, GE Healthcare, Gilead Sciences, Merck, Otsuka, Roche, Sumitomo Dainippon Pharma and Takeda. R.P., M.S., E.P. and R.S.F. declare no competing interests.